Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28044588 | 0.77 | NR1H2 (0.44) | USP30NR1H2GPR119LIPERORC | |
| SCHEMBL3829670 | 0.75 | KDM4E (0.45) | USP30NR1H2PIK3CDGPR119JAK1 | |
| SCHEMBL20078108 | 0.72 | DDB1 (0.53) | NR1H2PIK3CD | |
| SCHEMBL30390991 | 0.71 | CHRM2 (0.41) | PIK3CDGPR119JAK1 | |
| SCHEMBL30465899 | 0.71 | HCRTR1 (0.48) | NR1H2PIK3CDGPR119JAK1PDE10A | |
| SCHEMBL5938643 | 0.70 | NR1H2 (0.54) | USP30NR1H2GPR119LIPERORC | |
| SCHEMBL5940329 | 0.70 | NR1H2 (0.54) | USP30NR1H2GPR119LIPERORC | |
| SCHEMBL31073472 | 0.69 | MAPT (0.55) | NR1H2 | |
| SCHEMBL4869824 | 0.69 | MAPT (0.67) | NR1H2 | |
| SCHEMBL28044586 | 0.69 | NR1H2 (0.44) | USP30NR1H2PIK3CDGPR119LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085530-A | Fused tricyclic substituted amino six-membered ring derivative and application thereof in medicine | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-11-25 | — | — | CN | disclosed |